Warfarin in patients with stroke and reasons for discontinuation

Journal of Stroke and Cerebrovascular Diseases

Volumn 13, Issue 2, 2004, Pages 70-73

  Helgason, Cathy M ^a,c   Do, Mary Anthu ^a   Nutescu, Edith ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NONE   (United States)

Author keywords

Antithrombotic therapy; discontinuation of therapy; stroke; warfarin

Indexed keywords

ANTITHROMBOCYTIC AGENT; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING TENDENCY; FOLLOW UP; HEALTH CENTER; HUMAN; MEDICAL ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT GUIDANCE; PRIORITY JOURNAL; STROKE; THROMBOSIS PREVENTION; TREATMENT WITHDRAWAL;

EID: 3042762615     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2004.01.006     Document Type: Article

References (7)

1. Hirsh J., Fuster V., Ansell J., et al. AHA/ACC foundation guide to warfarin therapy. Circulation. 107:2003;. 1692-1622
2. Caplan L.R. Caplan's stroke A clinical approach. 3rd ed. 2000;17-50 Butterworth-Heineman, Boston
3. Hirsh J., Dalen J.E., et al. Oral anticoagulants Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119:(suppl 1):2001;8S-21S
4. Levine M.N., Raskob G., et al. Hemorrhagic complications of anticoagulant treatment. Chest. 119:(suppl 1):2001;108S-121S
5. Ansell J., Hirsh J., et al. Managing oral anticoagulant therapy. Chest. 119:(suppl 1):2001;22S-38S
6. Helgason C.M., Watkins F.A., Jobe T.H. Measurable differences between sequential and parallel diagnostic decision processes for determining stroke subtype A representation of interacting pathologies. Thromb Haemost. 88:2002;210-212
7. Milani R.V., Lavie C.J., Gilliland Y.E., et al. Overview of transoesophageal echocardiography for the chest physician. Cardiopulm Crit Care J. 124:2003;1081-1089